From: Doug Skrecky (oberon@vcn.bc.ca)
Date: Fri Aug 14 1998 - 00:19:47 MDT
Authors
Lockwood K. Moesgaard S. Yamamoto T. Folkers K.
Institution
Pharma Nord, Vejle, Denmark.
Title
Progress on therapy of
breast cancer with vitamin Q10 and the
regression of metastases.
Source
Biochemical & Biophysical Research Communications. 212(1):172-7, 1995 Jul 6.
Abstract
Over 35 years, data and knowledge have internationally evolved from
biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10;
CoQ10) and cancer, which led in 1993 to overt complete
regression of the tumors in two cases of breast
cancer. Continuing this research, three additional
breast cancer patients also underwent a
conventional protocol of therapy which included a daily oral
dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the
complete trials over 3-5 years. The numerous metastases in the liver of a
44-year-old patient "disappeared," and no signs of metastases were found
elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q10,
revealed no signs of tumor in the pleural cavity after six months, and her
condition was excellent. A 75-year-old patient with carcinoma in one
breast, after lumpectomy and 390 mg of CoQ10, showed no
cancer in the tumor bed or metastases. Control blood levels
of CoQ10 of 0.83-0.97 and of 0.62 micrograms/ml increased to 3.34-3.64 and to
3.77 micrograms/ml, respectively, on therapy with CoQ10 for
patients A-MRH and EEL.
This archive was generated by hypermail 2.1.5 : Fri Nov 01 2002 - 14:49:27 MST